0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

PLASMOCHIN, PLASMOCHIN WITH QUININE SALTS AND ATABRINE IN MALARIA THERAPY

PAUL F. RUSSELL, M.D.
Arch Intern Med (Chic). 1934;53(2):309-320. doi:10.1001/archinte.1934.00160080146006.
Text Size: A A A
Published online

The synthetic drug plasmochin, sometimes spelled plasmoquine, was developed in 1915. It is said to be (6 methoxy 8 αa methyl γ diethylamino butyl) aminoquinoline. Thus, although it contains quinoline, it is not synthetic quinine.

At first this synthetic remedy was sold as plasmochin simplex. Later, quinine was added to it, and the combined product was called plasmochin compound. Finally, a larger percentage of quinine was added, and the mixture was sold as plasmochin with quinine salts. The latter has also been called quinoplasmoquine. At one time it was called beprochin.

Plasmochin is sold in the following forms:

1. Plasmochin simplex or plain: A salt of plasmochin, which is usually sold in bottles of twenty-five tablets, each tablet containing the equivalent of 0.02 Gm., or ⅓ grain, of plasmochin hydrochloride.

2. Plasmochin compound: Usually marketed in bottles of fifty tablets. Each tablet contains the equivalent of 0.01 Gm., or ⅙

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();